Surfactant in the perinatal period

Area of Science:

• Neonatal Medicine
• Pulmonary Medicine
• Pharmacology

Background:

• Surfactant therapy is clinically available for infants with respiratory distress syndrome (RDS).
• Despite surfactant's effectiveness, lung disease persists in many preterm infants due to lung immaturity.
• Other factors beyond surfactant pools contribute to lung disease in preterm infants.

Purpose of the Study:

• To investigate the effects of corticosteroids on fetal lung development and their interaction with surfactant treatment.
• To determine if corticosteroids can augment the benefits of surfactant therapy in preterm infants.

Main Methods:

• Experimental models were used to assess the impact of corticosteroids on fetal lung physiology.
• Key lung function parameters including compliance, lung volumes, and pulmonary edema were measured.
• The interaction between corticosteroids and surfactant on lung mechanics was evaluated.

Main Results:

• Corticosteroids improved lung compliance and increased lung volumes in experimental models.
• Pulmonary edema was decreased, and the dose-response relationship of surfactant therapy was altered by corticosteroids.
• These beneficial effects were observed independently of changes in endogenous surfactant pools.

Conclusions:

• Corticosteroids significantly alter fetal lung maturation, improving key physiological parameters.
• Combined fetal maturation strategies (corticosteroids) and postnatal surfactant therapy are crucial for optimal outcomes in preterm infants.
• Corticosteroids augment the lung's response to surfactant treatment, offering a synergistic approach to managing preterm lung disease.